CapsoVisionCV
Recorded

CapsoVision 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration28 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

I will now hand the conference over to Leigh Salvo, Investor Relations. Please go ahead. Thank you, operator.

Leigh SalvoManaging Director

Good afternoon, everyone, and thank you for joining us for CapsoVision's third quarter 2026 earnings call. Joining me today are Johnny Wang, President and Chief Executive Officer, and Senior Vice President of Finance, David Garcia, as well as Doug Atkinson, Senior Vice President of Sales. Before we begin, please remember that today's remarks include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual events or results could differ materially due to a number of risks and uncertainties, including those mentioned in the most recent Form 10-Q filed by us with the SEC.

Leigh SalvoManaging Director

These forward-looking statements speak only as of the date of this call, and we expressly disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based. Our call today will cover the following agenda. Johnny will begin with an update on CapsoVision's business, target markets, and recent highlights from our pipeline development. Then Dave will walk through a commercial update and recent financial results. After our prepared remarks, we will open the call up for Johnny, David, and Doug to take your questions. With that, I'd like to turn the call over to Johnny Wang, CEO.

Johnny WangPresident and CEO

Johnny? Thank you, Lee, and good afternoon, everyone.

Johnny WangPresident and CEO

The third quarter was an important period for CapsoVision. We achieved a major regulatory milestone with FDA clearance of AI Highlights for CapsoCam Plus, completed enrollment for the clinical study supporting our planned CapsoCam Colon submission, and strengthened our balance sheet with an $18 million registered direct offering. Together, these accomplishments position us to advance our near-term commercial priorities while continuing to invest in the broader potential for our capsule endoscopy platform. Our progress underscores the strength of our team, our technology, and the opportunity ahead.

Johnny WangPresident and CEO

With AI Highlights cleared in the U.S., our second-generation CapsoCam Colon capsule advancing toward FDA submission, and continued progress in our pancreatic cancer trial, we are expanding what our platform can deliver to physicians and patients, bringing us closer to our long-term vision of identifying disease at its earliest, often precancerous stages, when intervention has the greatest potential to prevent cancer from developing. Let me start with AI Highlights, which received FDA clearance on September 25 and officially launched in the U.S. on November 2. This is a major achievement for CapsoVision and one that we believe meaningfully strengthens our position in small bowel capsule endoscopy. Our CapsoCam Plus capsule already offers a distinctive foundation for cameras, providing a 360-degree panoramic view of the small bowel.

Johnny WangPresident and CEO

This view allows physicians to see areas, including the inner curves at every turning point of the small bowel, that may be missed by traditional forward-facing capsule technology. We believe combining this imaging capability with our proprietary AI creates an especially compelling solution. AI Highlights builds on that advantage by helping physicians quickly identify images with suspected abnormalities. Importantly, our testing has shown that AI-assisted review can significantly reduce reading time and improve detection accuracy compared with manual review. For physicians, that means a more efficient review process, more accurate review, and additional level of diagnostic confidence. We are also focused on making the reading and reporting process as simple and intuitive as possible. We believe this combination sets our platform apart from competitive solutions. No other small bowel capsule on the market offers a comparable four-camera, 360-degree panoramic view together with FDA-cleared AI-assisted review.

Johnny WangPresident and CEO

CapsoCam Plus is also the only small bowel capsule with AI cleared for pediatric patients as young as two years old. These advantages give physicians a differentiated imaging and review platform and expands the patients who can benefit from our technology. Our priority now is ongoing physician education, custom onboarding, and helping practices evaluate AI Highlights in their workflows. Our team also recently attended the American College of Gastroenterology's annual meeting in Nashville, where we had an excellent opportunity to showcase AI Highlights to the GI community. The response from physicians was extremely encouraging, with many expressing enthusiasm about the faster, more accurate review and an eagerness to begin using the technology in their practices. In short, our approach brings together the panoramic imaging of CapsoCam Plus, AI Highlights within CapsoView, and the flexibility of CapsoCloud.

Johnny WangPresident and CEO

Together, these technologies provide more complete visualization of the small bowel, faster and more accurate video review, and the ability for physicians to review study anytime, anywhere. Because our platform is fully cloud-based, there is no need for providers to install or maintain on-site servers or IT infrastructure. We believe these advantages set CapsoVision apart from competitive solutions and can support broader adoption over time. Turning to CapsoCam Colon, we completed enrollment and data collection, including physician reading of capsule videos with and without AI assistance for the clinical study supporting our planned FDA submission. This is a significant milestone and the culmination of extensive clinical engineering and regulatory work. I want to take a moment to recognize the tremendous dedication and hard work of our team, whose commitment and perseverance have been instrumental in getting us to this point. I am proud of what we have accomplished together.

Johnny WangPresident and CEO

We remain on track for submission before year-end 2026. Our second-generation colon platform is designed to bring the advantages of panoramic imaging and AI-assisted review to a much larger market. Based on our estimates, the initial U.S. annual addressable market for patients at higher risk from colonoscopy, all those with an incomplete procedure, is approximately $1 billion. Longer term, the scale of the colon opportunity has the potential to address a market estimated to be over $10 billion, which is pending with the recommendation for routine colon cancer screening dropping from 50 to 45 years old. We continue to expand the clinical footprint of the CapsoCam UGI study for pancreatic cancer detection. Building on the current two active community-based clinical sites, site activation is advancing over a dozen large-volume centers with pancreatic cancer expertise, establishing a foundation to accelerate clinical enrollment.

Johnny WangPresident and CEO

This remains an early-stage program, but we believe it illustrates the breadth of potential applications for our imaging platform. Finally, in mid-September, we completed an $18 million registered direct offering with several existing shareholders. We appreciate their continued support and commitment to our strategy. This financing provides additional resources to support the AI rollout, planned colon submission, and ongoing clinical development. Dave will provide more detail on our cash position shortly. Our focus is clear: execute the AI launch, convert the customer interest into adoption, complete the colon regulatory submission, and continue advancing our broader pipeline. With that, I will turn the call over to Dave.

David GarciaSVP of Finance

Thank you, Johnny. Starting with our commercial performance, the third quarter reflected a competitive pricing environment in the U.S. for small bowel capsule endoscopy, even as we continued to make progress in expanding our customer base. During the third quarter, we shipped 8,464 CapsoCam Plus capsules compared to 8,336 in Q3 2025. Today, our technology is protected by 85 issued U.S. patents, reinforcing our strong foundation in IP and clinical innovation. We added several new accounts with particularly encouraging activity in pediatric practices and larger gastroenterology and hospital networks such as Carilion Health Systems, Methodist Hospital Systems, and additional locations within Gastro Health and Kaiser Permanente. In total, we closed 34 new accounts, including nine hospital systems, four pediatric hospital clinics, and 21 adult GI clinics. We view new account additions and physician engagement as being important leading indicators, as commercial gains ultimately signal stronger revenue performance.

David GarciaSVP of Finance

As of September 30, 2026, CapsoCam Plus for small bowel screening has been used by more than 184,000 patients compared to 151,000 a year ago across the U.S. and internationally. AI Highlights for small bowel officially launched in the U.S. on November 2nd. We believe it gives our sales team a powerful new way to demonstrate the clinical and workflow value of CapsoCam Plus, including reading efficiency, accuracy, and additional diagnostic confidence. We are prioritizing physician education, customer onboarding, and opportunities for customers to evaluate our solution against competitive alternatives. Turning to our financial results. Third quarter revenue was $3.6 million, compared with $3.5 million in the third quarter of 2025, a change of 1%, and average selling price was stable year-over-year. Gross profit was $1.8 million, compared with $1.9 million in the prior year quarter. Gross margin was 49%, compared with 54% last year.

David GarciaSVP of Finance

Gross margin in the quarter was impacted by higher material costs due to increasing prices of flash memory, a one-time charge for inventory obsolescence, and higher stock-based compensation expense. Operating expenses were $9.1 million, compared with $9.9 million in the third quarter of 2025, reflecting continued expense management while supporting our clinical and development programs, including the CapsoCam Colon pivotal study. With the study now complete, we expect our associated clinical expenses to decrease, providing an opportunity for a further operating expense decline as we continue advancing our broader product pipeline. Net loss was $7.3 million, or $0.15 a share, compared with a net loss of $7.9 million, or $0.17 per share, in the prior year period.

David GarciaSVP of Finance

We ended September 30th with $21.8 million in cash and cash equivalents, which included proceeds from a registered direct offering with existing shareholders that closed on September 18th and generated net proceeds of approximately $17.8 million. This capital strengthens our balance sheet and extends our expected cash runway. We also utilized our ATM facility established earlier this year during Q3. We sold 276,446 shares under the ATM for net proceeds of $1.7 million. The ATM provides additional financing flexibility, although any use will depend on market conditions and the needs of the business. As we approach year-end, our commercial priorities center on supporting the November 2nd U.S. launch of AI Highlights, expanding adoption across new and existing accounts, and building on the customer relationships established during the year. We believe our combination of panoramic imaging, integrated AI, and cloud-connected workflow can strengthen our competitive position over time.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day